治疗性抗体帕博利珠单抗阻断PD-1介导的免疫抑制的结构基础。 - Suppr

Suppr

超能文献

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.

作者信息

Na Zhenkun, Yeo Siok Ping, Bharath Sakshibeedu R, Bowler Matthew W, Balıkçı Esra, Wang Cheng-I, Song Haiwei

机构信息

Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673, Singapore.

Singapore Immunology Network, 8a Biomedical Grove, Singapore 138648, Singapore.

出版信息

Cell Res. 2017 Jan;27(1):147-150. doi: 10.1038/cr.2016.77. Epub 2016 Jun 21.

DOI:10.1038/cr.2016.77

PMID:27325296

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5223238/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84fa/5223238/c061688c0975/cr201677f1.jpg

相似文献

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.治疗性抗体帕博利珠单抗阻断PD-1介导的免疫抑制的结构基础。

Cell Res. 2017 Jan;27(1):147-150. doi: 10.1038/cr.2016.77. Epub 2016 Jun 21.

Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.PD-1 与肿瘤免疫检查点治疗中使用的抗体药物 tislelizumab 复合物的晶体结构。

Biochem Biophys Res Commun. 2020 Jun 18;527(1):226-231. doi: 10.1016/j.bbrc.2020.04.121. Epub 2020 May 1.

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.免疫检查点受体 PD-1 及其配体 PD-L1/PD-L2 的结构生物学。

Structure. 2017 Aug 1;25(8):1163-1174. doi: 10.1016/j.str.2017.06.011.

Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.帕博利珠单抗：PD -1抑制作为癌症治疗策略

Drugs Today (Barc). 2015 Jan;51(1):7-20. doi: 10.1358/dot.2015.51.1.2250387.

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.癌症免疫疗法中单克隆抗体阻断检查点的结构基础。

Nat Commun. 2016 Oct 31;7:13354. doi: 10.1038/ncomms13354.

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.PD-1 中的一个意想不到的 N 端环主导了 nivolumab 的结合。

Nat Commun. 2017 Feb 6;8:14369. doi: 10.1038/ncomms14369.

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood.监测与源自一滴外周血的T细胞结合的PD-1阻断抗体。

J Vis Exp. 2020 Feb 5(156). doi: 10.3791/60608.

Pembrolizumab for the treatment of melanoma.帕博利珠单抗用于治疗黑色素瘤。

Expert Rev Clin Pharmacol. 2015;8(5):515-27. doi: 10.1586/17512433.2015.1061430. Epub 2015 Jul 9.

The binding epitope of sintilimab on PD-1 revealed by AbMap.AbMap 揭示的信迪利单抗与 PD-1 的结合表位

Acta Biochim Biophys Sin (Shanghai). 2021 Apr 15;53(5):628-635. doi: 10.1093/abbs/gmab020.

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.与人类程序性死亡受体1（PD-1）结合的治疗性抗体帕博利珠单抗的高分辨率晶体结构。

Sci Rep. 2016 Oct 13;6:35297. doi: 10.1038/srep35297.

引用本文的文献

Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.癌症中的免疫逃逸：机制与前沿治疗方法。

Signal Transduct Target Ther. 2025 Jul 31;10(1):227. doi: 10.1038/s41392-025-02280-1.

Unveiling the best immune checkpoint inhibitor-based therapy for metastatic renal cell carcinoma in the first-line setting: an updated systematic review and Bayesian network analysis.揭示一线治疗转移性肾细胞癌的最佳免疫检查点抑制剂疗法：一项更新的系统评价和贝叶斯网络分析。

Ther Adv Med Oncol. 2025 Jul 6;17:17588359251353259. doi: 10.1177/17588359251353259. eCollection 2025.

Unifying sequence-structure coding for advanced protein engineering a multimodal diffusion transformer.用于先进蛋白质工程的统一序列结构编码——一种多模态扩散变换器。

Chem Sci. 2025 May 15. doi: 10.1039/d5sc02055g.

Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma.替雷利珠单抗用于治疗晚期食管鳞状细胞癌。

Future Oncol. 2025 May;21(12):1473-1481. doi: 10.1080/14796694.2025.2495542. Epub 2025 Apr 21.

Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial.局部晚期口腔鳞状细胞癌新辅助免疫治疗联合或不联合化疗：随机、双臂、2期试验

Cell Rep Med. 2025 Feb 18;6(2):101930. doi: 10.1016/j.xcrm.2025.101930. Epub 2025 Jan 30.

The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer.微小RNA与程序性死亡蛋白1/程序性死亡配体1信号轴：肺癌免疫治疗靶点的宝库

Cell Death Discov. 2024 Sep 29;10(1):414. doi: 10.1038/s41420-024-02182-1.

Residue-Specific Epitope Mapping of the PD-1/Nivolumab Interaction Using X-ray Footprinting Mass Spectrometry.使用X射线足迹质谱法对PD-1/纳武单抗相互作用进行残基特异性表位定位

Antibodies (Basel). 2024 Sep 19;13(3):77. doi: 10.3390/antib13030077.

PD-1 Targeted Antibody Discovery Using AI Protein Diffusion.利用人工智能蛋白质扩散进行 PD-1 靶向抗体发现。

Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241275947. doi: 10.1177/15330338241275947.

IL-12 and PD-1 peptide combination gene therapy for the treatment of melanoma.白细胞介素-12与程序性死亡蛋白-1肽联合基因疗法治疗黑色素瘤

Mol Ther Nucleic Acids. 2024 Jul 16;35(3):102267. doi: 10.1016/j.omtn.2024.102267. eCollection 2024 Sep 10.

Glycosylation and Its Role in Immune Checkpoint Proteins: From Molecular Mechanisms to Clinical Implications.糖基化及其在免疫检查点蛋白中的作用：从分子机制到临床意义

Biomedicines. 2024 Jun 28;12(7):1446. doi: 10.3390/biomedicines12071446.

本文引用的文献

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.人程序性死亡蛋白1（PD-1）及其配体PD-L1复合物的结构

Structure. 2015 Dec 1;23(12):2341-2348. doi: 10.1016/j.str.2015.09.010. Epub 2015 Oct 22.

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab.全长人源抗 PD1 治疗性 IgG4 抗体 pembrolizumab 的结构。

Nat Struct Mol Biol. 2015 Dec;22(12):953-8. doi: 10.1038/nsmb.3129. Epub 2015 Nov 23.

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.免疫反应的变阻器：PD-1 的独特特性及其在临床应用中的优势。

Nat Immunol. 2013 Dec;14(12):1212-8. doi: 10.1038/ni.2762.

Combination checkpoint blockade--taking melanoma immunotherapy to the next level.联合检查点阻断——将黑色素瘤免疫疗法提升到新高度。

N Engl J Med. 2013 Jul 11;369(2):187-9. doi: 10.1056/NEJMe1305484. Epub 2013 Jun 2.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.拉罗替尼（anti-PD-1）治疗黑色素瘤的安全性和肿瘤应答。

N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.

Structure and interactions of the human programmed cell death 1 receptor.人程序性细胞死亡受体 1 的结构和相互作用。

J Biol Chem. 2013 Apr 26;288(17):11771-85. doi: 10.1074/jbc.M112.448126. Epub 2013 Feb 15.

The blockade of immune checkpoints in cancer immunotherapy.癌症免疫疗法中的免疫检查点阻断。

Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2.程序性死亡蛋白1（PD-1）与其配体PD-L2复合物的晶体结构。

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10483-8. doi: 10.1073/pnas.0804453105. Epub 2008 Jul 18.

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.程序性死亡蛋白1（PD-1）/程序性死亡配体1（PD-L1）复合物类似于抗体和T细胞受体的抗原结合Fv结构域。

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3011-6. doi: 10.1073/pnas.0712278105. Epub 2008 Feb 14.

Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.癌症免疫：T淋巴细胞与肿瘤细胞相互作用中的攻击与逃逸

Immunol Rev. 2002 Oct;188:97-113. doi: 10.1034/j.1600-065x.2002.18809.x.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验